Arena’s Comeback Continues with $800M Deal for Blood Disease Drug

Arena Pharmaceuticals continued its comeback Thursday, netting a whopping $800 million up front in a deal that hands United Therapeutics another experimental drug for the rare blood disorder pulmonary arterial hypertension (PAH).